subscribeSubscribe
AbbVie looks to extend Rinvoq`s reach with filings for giant cell arteritis

AbbVie looks to extend Rinvoq`s reach with filings for giant cell arteritis
PRESS RELEASE
13 Jul 2024
Share Share
RINVOQ Available For Pediatric Polyarticular JIA And Psoriatic Arthritis

RINVOQ Available For Pediatric Polyarticular JIA And Psoriatic Arthritis
PR NEWSWIRE
04 Jun 2024
Share Share
J&J acquires experimental skin disorder drug for $1.25 billion

J&J acquires experimental skin disorder drug for $1.25 billion
Ben Fidler BIOPHARMADIVE
29 May 2024
Share Share
RINVOQ® Beats DUPIXENT® in Head-to-Head Atopic Dermatitis Study

RINVOQ® Beats DUPIXENT® in Head-to-Head Atopic Dermatitis Study
PR NEWSWIRE
25 Apr 2024
Share Share
AbbVie`s phase 3 Select -GCA study of Upadacitinib showed positive results

AbbVie`s phase 3 Select -GCA study of Upadacitinib showed positive results
INDINPHARMAPOST
23 Apr 2024
Share Share
Upadacitinib`s Phase 3 GCA Study Met Primary Endpoint

Upadacitinib`s Phase 3 GCA Study Met Primary Endpoint
PR NEWSWIRE
18 Apr 2024
Share Share
AbbVie`s Rinvoq passes muster in yet another autoimmune disease

AbbVie`s Rinvoq passes muster in yet another autoimmune disease
Eric Sagonowsky FIERCE PHARMA
18 Apr 2024
Share Share
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion

AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
REUTERS
03 Feb 2024
Share Share
AbbVie files patent litigation against generic Rinvoq makers

AbbVie files patent litigation against generic Rinvoq makers
Fraiser Kansteiner FIERCE PHARMA
23 Nov 2023
Share Share
FDA Confirms Paragraph IV Patent Litigation for Upadacitinib Extended-release Tablets 45 mg

FDA Confirms Paragraph IV Patent Litigation for Upadacitinib Extended-release Tablets 45 mg
FDA
31 Oct 2023
Share Share